The Technology and Life Sciences team advised Spear Bio on the closing of its $45 million Series A financing. The oversubscribed round was co-led by Foresite Capital and Bio-Techne Corporation, with additional participation from existing investors including Maverick Ventures, Yonjin Capital and CDH Investments.
Spear Bio – founded in 2021 and headquartered in Woburn, Massachusetts – is an innovative leader in providing scalable solutions for ultra-sensitive protein biomarker measurements. Spear Bio’s proprietary technology, Successive Proximity Extension Amplification Reaction (SPEAR), employs a unique 2-factor authentication mechanism to precisely measure protein biomarkers at attomolar level from sub-microliter sample volume.
The Goodwin team was led by Mark Macenka, Kristin Gerber, Jason Goldfarb, Cody Goodwin and Matthew Salit and included Kathleen Kean, Rich Matheny, Ce Li and Gozde Guckaya with invaluable assistance from Kim Larie, Mehack Ali and Pat Robichaud.
For additional details on the closing, please read the press release and coverage in the Boston Business Journal.